Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials

Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.